Literature DB >> 12421989

The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells.

Mariana J Kaplan1, Emily E Lewis, Eric A Shelden, Emily Somers, Robert Pavlic, William J McCune, Bruce C Richardson.   

Abstract

Individuals with systemic lupus erythematosus show evidence of a significant increase in monocyte apoptosis. This process is mediated, at least in part, by an autoreactive T cell subset that kills autologous monocytes in the absence of nominal Ag. We have investigated the apoptotic pathways involved in this T cell-mediated process. Expression of the apoptotic ligands TRAIL, TNF-like weak inducer of apoptosis (TWEAK), and Fas ligand on lupus T cells was determined, and the role of these molecules in the monocyte apoptotic response was examined. We report that these apoptotic ligands mediate the autologous monocyte death induced by lupus T cells and that this cytotoxicity is associated with increased expression of these molecules on activated T cells, rather than with an increased susceptibility of lupus monocytes to apoptosis induced by these ligands. These results define novel mechanisms that contribute to increased monocyte apoptosis characterizing patients with lupus. We propose that this mechanism could provide a source of potentially antigenic material for the autoimmune response and interfere with normal clearing mechanisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421989     DOI: 10.4049/jimmunol.169.10.6020

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  B lymphocytes are resistant to death receptor 5-induced apoptosis.

Authors:  Roslyn N Crowder; Hong Zhao; W Winn Chatham; Tong Zhou; Robert H Carter
Journal:  Clin Immunol       Date:  2011-01-28       Impact factor: 3.969

2.  Impact of antihypertensive drugs on TNF-like weak inducer of apoptosis.

Authors:  Xiaoqi Shen
Journal:  Clin Rheumatol       Date:  2012-03-13       Impact factor: 2.980

3.  Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement.

Authors:  Noha A Azab; Hanaa M Rady; Samar A Marzouk
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

4.  Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38 mitogen-activated protein kinase activation and signal transduction in peripheral blood mononuclear cells from patients with lupus nephritis.

Authors:  Liu Zhi-Chun; Zhou Qiao-Ling; Liu Zhi-Qin; Li Xiao-Zhao; Zuo Xiao-xia; Tang Rong
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 5.  TWEAK as a target for therapy in systemic lupus erythematosus.

Authors:  Rui-Xue Leng; Hai-Feng Pan; Wei-Zi Qin; Chao Wang; Li-Li Chen; Jin-Hui Tao; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

6.  Acetylated histones contribute to the immunostimulatory potential of neutrophil extracellular traps in systemic lupus erythematosus.

Authors:  E Pieterse; J Hofstra; J Berden; M Herrmann; J Dieker; J van der Vlag
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

7.  Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.

Authors:  Gerald R Galluppi; Nicolas Wisniacki; Chris Stebbins
Journal:  Br J Clin Pharmacol       Date:  2016-04-08       Impact factor: 4.335

Review 8.  The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus.

Authors:  Bernadete L Liphaus; Maria Helena Bittencourt Kiss
Journal:  Clinics (Sao Paulo)       Date:  2010-03       Impact factor: 2.365

Review 9.  Biomarkers for lupus nephritis: a critical appraisal.

Authors:  Chi Chiu Mok
Journal:  J Biomed Biotechnol       Date:  2010-04-19

10.  Increased expression of Toll-like receptor 4 in peripheral blood leucocytes and serum levels of some cytokines in patients with ankylosing spondylitis.

Authors:  Z-X Yang; Y Liang; Y Zhu; C Li; L-Z Zhang; X-M Zeng; R-Q Zhong
Journal:  Clin Exp Immunol       Date:  2007-04-25       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.